CYP1B1-IN-4 is a 2,4-diarylthiazole compound with selectively CYP1B1 inhibition.

4-PPBP is a σ ligand and selective non-competitive antagonist at recombinant NR1a/2B NMDA receptors expressed in Xenopus oocytes. 4-PPBP protects against newborn excitotoxic brain injury by stabilizing the mitochondrial membrane potential in vitro and inhibiting microglial activation in vivo. 4-PPBP modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.

PROTAC MDM2 Degrader-2 is a MDM2 degrader based on PROTAC technology.

CAY10462 is the hydrochloride salt of CAY10434 and selective inhibitor of the 20-HETE synthase CYP4A11 exhibiting an IC50 of 8.8 nM when tested in human renal microsomes.4 CAY10434 is nearly 200 times less potent as an inhibitor of 1A, 1C, and 3A CYP450.

LY 235959 is a competitive NMDA receptor antagonist.

PARP-1-IN-4 is a PARP-1 inhibitor.

Beloxepin, also known as ADL-6906; ORG-4428, is an oral dual selective serotonin and norepinephrine uptake inhibitor.

CDK8-IN-12 is an orally active, potent CDK8 inhibitor.

PDCD4-IN-1(compound 20031600) is a PDCD4 inhibitor.

LY 43578 is an aromatase inhibitor.

HT-61, also known as HY-50A, is a pyrroloquinolone antibiotic potentially for the treatment of staphylococcal infections. HT61 was effective at reducing biofilm viability and was associated with increased expression of cell wall stress and division proteins, confirming its potential as a treatment for S. aureus biofilm infections. HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo.

VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor.

SHP099 is a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor with IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM. SHP099 exhibits dose-dependent pathway inhibition and antitumor activity in xenograft models. SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1). Because it is an oncoprotein associated with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest.

VU0364572 free base is an orally active and selective allosteric agonist of the M1 muscarinic receptor.

Tubulin inhibitor 32 is a potent and orally active tubulin inhibitor.

NDM-1 inhibitor-3 (Compound 89) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor

ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3.

CpCDPK1/TgCDPK1-IN-3 (Compound 20) is a CpCDPK1 and TgCDPK1 inhibitor

S1R agonist 2 (Compound 8b) is a selective S1R agonist.

(-)-GSK598809 is an isomer of GSK598809. GSK598809 is a selective D(3)R antagonist recently progressed in Phase I trials. GSK-598809 may decrease the rewarding effects of contextual cues associated with drug intake preclinically, which may reduce drug craving in humans.

Prulifloxacin, also known as NM-441, is an inhibitor of bacterial DNA gyrase used to treat urinary tract infections. Prulifloxacin is an oral fluoroquinolone with a broad in vitro activity spectrum against Gram positive and negative bacteria and among fluoroquinolones has the lowest power of inducing resistance. In vitro and in vivo studies have shown its clinical efficacy and pathogen eradication.

L-Tyrosine is an aromatic, polar, non-essential amino acid that contains a highly reactive α-amino, α-carboxyl, and phenolic hydroxyl group. L-tyrosine modulates biofilm formation of Bacillus cereus ATCC 14579. L-Tyrosine Limits Mycobacterial Survival in Tuberculous Granuloma.

SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM.

Mtb-IN-2 (compound 10c) is an antimicrobial agent against Mycobacterium tuberculosis (Mtb).

Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor.

DC-Y13-27, a derivative of DC-Y13, is a YTHDF2 inhibitor (KD: 37.9 μM).

sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue.

STAT3-IN-15 is a potent and orally active STAT3 inhibitor.

FC-116 is a Tubulin inhibitor that effectively inhibits tumor growth in mice.

URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor.